Related Experiment Video
Updated: May 21, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Stent thrombosis in patients with chronic kidney disease
Michael Donahue1, Carlo Briguori
1Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples, Italy.
Insights
Patients with chronic kidney disease face higher risks of stent thrombosis (ST) after percutaneous coronary intervention. This review examines evidence on ST with drug-eluting stents in this high-risk population.
Area of Science:
- Cardiology
- Nephrology
- Biomedical Engineering
Background:
- Chronic kidney disease (CKD) significantly increases the risk of adverse cardiac events, including death and myocardial infarction.
- Stent thrombosis (ST), a severe complication after percutaneous coronary intervention (PCI), remains a concern despite advances in treatment.
- Identifying high-risk patients for ST is crucial for developing effective preventive strategies.
Purpose of the Study:
- To review the existing evidence on stent thrombosis (ST) in patients with chronic kidney disease (CKD).
- To evaluate the safety and efficacy of drug-eluting stents (DES) in this specific patient group.
- To highlight the need for improved risk stratification and prevention of ST in CKD patients undergoing PCI.
Main Methods:
- Comprehensive literature search for studies on ST, PCI, drug-eluting stents, and chronic kidney disease.
- Analysis of data regarding the incidence, risk factors, and outcomes of ST in CKD patients.
- Synthesis of evidence to assess the role of DES in managing ST risk in this population.
Main Results:
- CKD is a well-established predictor of adverse cardiac events post-PCI.
- While new therapies have reduced ST rates, it remains a significant cause of morbidity and mortality.
- Evidence regarding the specific impact of DES on ST in CKD patients requires further examination.
Conclusions:
- Despite therapeutic advancements, stent thrombosis (ST) continues to pose a serious threat to patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention.
- Further research is needed to refine preventive strategies and identify high-risk CKD patients susceptible to ST, particularly concerning the use of drug-eluting stents.
- Optimizing management of CKD patients undergoing PCI is essential to mitigate the risk of life-threatening stent thrombosis.
Abstract:
Chronic kidney disease is a strong predictor of adverse cardiac events, including death, myocardial infarction and stent thrombosis (ST), after percutaneous coronary intervention. In the past few years, the development of new therapeutic strategies (including both drugs and devices) and a more complete understanding of the pathophysiology and predictive factors of thrombosis have led to a significant reduction of this complication. Despite this, ST still remains a dramatic event due to its morbidity and mortality. Further efforts should be pursued to identify patients at high risk of ST in order to adopt a more effective preventive strategy. This review sought to examine the total weight of evidence regarding ST with the use of drug-eluting stents in patients with chronic kidney disease.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology
Cardiac Catheterization I: Pre-Procedure Overview

